<DOC>
	<DOC>NCT01551212</DOC>
	<brief_summary>This trial will evaluate the efficacy of Everolimus in combination tacrolimus versus a standard immunosuppressive regimen concerning kidney function in liver transplant recipients.</brief_summary>
	<brief_title>Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Inclusion criteria: Male or female recipients of a fullsize liver allograft, aged 18 to 65 years. Exclusion criteria: Patients with thrombocytopenia (platelets &lt;50,000/mm³), with an absolute neutrophil count of &lt;1,000/mm³ or leucopenia (leucocytes &lt;2000/mm³), with anemia with Hb &lt; 8g/dl at time of screening Patients with uncontrolled hypercholesterolemia (&gt;350mg/dL; &gt;9mmol/L) or hypertriglyceridemia (&gt;750 mg/dL; &gt;8.5 mmol/L) at time of screening History of malignancy of any organ system within the past 5 years whether or not there is evidence of local recurrence or metastases, other than nonmetastatic basal or squamous cell carcinoma of the skin or HCC (see next criteria). Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>kidney function</keyword>
</DOC>